Grace Therapeutics GRCE
NASDAQ GRCE
$2.00 +0.02 (+1.01%)
As of: Oct 21, 2026 · 3:39 PM EDT

Grace Therapeutics (GRCE) Total Debt (2019)

Updated

Grace Therapeutics' Total Debt came in at $1.36 million for fiscal Q4 2019 (quarter ended Mar 31, 2019).

Analysis

Grace Therapeutics (GRCE) Total Debt (2019) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Eli Lilly 1,137.42 Bn 1,106.00 Bn 19.71 Bn 54.91 Bn
2 Johnson & Johnson 617.98 Bn 536.51 Bn 17.26 Bn 49.04 Bn
3 AbbVie 502.80 Bn 475.92 Bn 12.70 Bn 70.82 Bn
4 Merck 368.67 Bn 323.05 Bn 12.21 Bn 53.91 Bn
5 Novartis Ag 298.36 Bn 262.35 Bn 11.24 Bn 9.59 Bn
6 Astrazeneca 261.17 Bn 234.85 Bn 12.86 Bn 32.35 Bn
7 Amgen 237.18 Bn 192.58 Bn 7.24 Bn 57.30 Bn
8 Gilead Sciences 191.11 Bn 165.31 Bn 6.22 Bn 26.25 Bn
9 Pfizer 169.83 Bn 116.48 Bn 10.94 Bn 63.19 Bn
10 Grace Therapeutics 34.28 Mn -31.99 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2019 1.36 Mn
API Access

Grace Therapeutics Total Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-debt&ticker=GRCE&period=max&api_key=YOUR_API_KEY